


The *Crocus sativus* compounds *trans*-crocin 4 and *trans*-crocetin modulate the amyloidogenic pathway and tau misprocessing in Alzheimer disease neuronal cell culture models

Ioanna Chalatsa^{1†}, Demetrios A. Arvanitis^{2†}, Nikolaos Stavros Koulakiotis³, Athina Giagini¹, Alexios Leandros Skaltsounis⁴, Zeta Papadopoulou-Daifoti^{5‡}, Anthony Tsbopoulos^{3,5}, *Despina Sanoudou^{1,2,6*}


Correspondence:

Despina Sanoudou, PhD FACMG


E-mail dsanoudou@med.uoa.gr




Supplementary Figure 1: Positive-ion ESI product ion spectrum of the $[M+Na]^+$ precursor ions of *trans*-crocetin utilizing a Waters Premier quadrupole reflectron time-of-flight (QqRTOF) mass spectrometer.



Supplementary Figure 2: Positive-ion ESI product ion spectrum of the $[M+Na]^+$ precursor ions of *trans*-crocin-4 utilizing a Waters Premier quadrupole reflectron time-of-flight (QqRTOF) mass spectrometer.



Supplementary Figure 3: Differentiation of SH-SY5Y, SH-SY5Y-APP, PC12 and PC12-htau to neuron-like cells. Representative photos of SH-SY5Y and SH-SY5Y-APP (A), PC12 and PC12-htau naive cells (B) at 6 and 7 days, respectively, of proliferation and differentiation (C and D). Differentiated cells exhibit decreased proliferation, and increased dendritic and neuritic-like projections compared to naive cells.



Supplementary Figure 4: Immunoblotting assessment of the tau levels and phosphorylation after treatment of differentiated PC12 cells with *trans-crocic acid* or *trans-crocetin*. (A) Immunoblotting detection of pThr231-tau, pSer199/Ser202-tau, total tau, with actin as internal control of protein expression. (B) Diagrammatic presentation of quantified protein expression (* $p < 0.05$, when compared test treatment versus DMSO in post-hoc one-way ANOVA, $n=3$).

Supplementary Table 1: Primary antibodies and electrophoresis conditions

| Protein | Catalogue number | Company | MW | Host | Gel |
|-------------------------------------|-------------------------|-----------------------------|----------------|------------------------|--------------------|
| Cellular APP | R1(57) | By Prof. Efthimiopoulos Lab | ~110 kDa | Polyclonal anti-rabbit | 10% Tris-Glycine |
| APP-C99 | R1(57) | By Prof. Efthimiopoulos Lab | 12 kDa | Polyclonal anti-rabbit | 4-12% Bis-Tris |
| APP-C83 | R1(57) | By Prof. Efthimiopoulos Lab | 10 kDa | Polyclonal anti-rabbit | 4-12% Bis-Tris |
| sAPPα | SIG-39320 | Covance | ~100 kDa | Monoclonal anti-mouse | 16.5% Tris-Tricine |
| beta-amyloid | SIG-39320 | Covance | 4 kDa | Monoclonal anti-mouse | 16.5% Tris-Tricine |
| BACE1 | MAB5308 | Chemicon Millipore | 56 kDa | Monoclonal anti-mouse | 10% Tris-Glycine |
| PSEN1 | AB5308 | Chemicon Millipore | Multiple forms | Polyclonal anti-rabbit | 10% Tris-Glycine |
| PSEN2 | 2192 | Cell Signaling | Multiple forms | Polyclonal anti-rabbit | 10% Tris-Glycine |
| Total tau (Tau5 antibody) | ab80579 | Abcam | 79 kDa | Monoclonal anti-mouse | 10% Tris-Glycine |
| pSer199/Ser202-tau | AB9674 | Chemicon Millipore | 79 kDa | Polyclonal anti-rabbit | 10% Tris-Glycine |
| pThr231-tau | ab151559 | Abcam | 46 kDa | Monoclonal anti-rabbit | 10% Tris-Glycine |
| pERK1/2 | 4370 | Cell Signaling | 44/42 kDa | Monoclonal anti-rabbit | 10% Tris-Glycine |
| ERK1/2 | 4695 | Cell Signaling | 44/42 kDa | Monoclonal anti-rabbit | 10% Tris-Glycine |
| pSer9-GSK3β | 9323P | Cell Signaling | 46 kDa | Monoclonal anti-rabbit | 10% Tris-Glycine |
| GSK3β | 9315S | Cell Signaling | 46 kDa | Monoclonal anti-rabbit | 10% Tris-Glycine |

| | | | | | |
|--------------|-----------|-----------------------|--------|--------------------------|--|
| Actin | MAB1501 | Chemicon Millipore | 42 kDa | Monoclonal anti-mouse | |
| GAPDH | SC-365062 | Santa Cruz | 37 kDa | Monoclonal anti-mouse | |